Multicomponent mixtures for cryoprotection and ligand solubilization  by Ciccone, Lidia et al.
Multicomponent mixtures for cryoprotection and ligand
solubilization$
Lidia Cicconea,b, Laura Veraa,1, Livia Tepshia,b, Lea Rosaliaa,b, Armando Rossellob,
Enrico A. Sturaa,*
aCEA, iBiTec-S, Service d’Ingénierie Moléculaire des Protéines, Laboratoire de Toxinologie Moléculaire et Biotechnologies, Gif-sur-Yvette, F-91191, France
bDipartimento di Farmacia, Università di Pisa, Via Bonanno 6, 56126 Pisa, Italy
A R T I C L E I N F O
Article history:
Received 18 December 2014
Received in revised form 10 April 2015
Accepted 31 May 2015
Available online 23 June 2015
A B S T R A C T
Mixed cryoprotectants have been developed for the solubilization of ligands for crystallization of
protein–ligand complexes and for crystal soaking. Low afﬁnity lead compounds with poor solubility are
problematic for structural studies. Complete ligand solubilization is required for co-crystallization and
crystal soaking experiments to obtain interpretable electron density maps for the ligand. Mixed cryo-
preserving compounds are needed prior to X-ray data collection to reduce radiation damage at
synchrotron sources. Here we present dual-use mixes that act as cryoprotectants and also promote the
aqueous solubility of hydrophobic ligands. Unlike glycerol that increases protein solubility and can cause
crystal melting the mixed solutions of cryo-preserving compounds that include precipitants and
solubilizers, allow for worry-free crystal preservation while simultaneously solubilizing relatively
hydrophobic ligands, typical of ligands obtained in high-throughput screening. The effectiveness of these
mixture has been conﬁrmed on a human transthyretin crystals both during crystallization and in ﬂash
freezing of crystals.
ã 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
High-throughput screening is used to select among libraries of
millions of compounds those that bind to a target protein, inhibit a
particular enzymatic reaction or block a cellular transport
mechanism. Typically the chemical compounds are dissolved in
dimethyl sulfoxide (DMSO) [1] to produce an aqueous solution.
This solution is diluted during the screening to ensure that the
concentration of DMSO does not exceed 10%; as higher concen-
trations can be damaging to the target protein [2]. The discovered
‘hits’ are unlikely to be suitable for clinical use, but are good
building blocks from which drugs may evolve. Structural studies
are often essential to transform these hits into leads and eventually
into potential drugs that can undergo clinical trials. The poor
solubility of ligands is a problem for the crystallization of protein-
complexes, more so when the ligand or fragment has a low afﬁnity
for its target. For co-crystallization, the ligand must be soluble in
the crystallization precipitant so as to be in excess compared to the
protein. The protein concentration needed for crystal growth starts
from around 50 mM into the millimolar range. The crystallization
conditions, including additives, must be chosen in such a manner
as to ensure that the ligand remains in solution throughout the
crystallization process.
In a previous study, by mixing cryo-preserving compounds that
act as precipitants with compounds that have the opposite effect
we developed a set of multicomponent mixtures that could be
combined with a precipitant and a buffer so as to be able to prepare
crystals for X-ray data collection at high intensity synchrotron
facilities without tribulation [3]. These mixtures can stabilize
crystals for periods long enough for ligand soaking experiments.
The presence of DMSO, not higher than 10%, in addition to the other
cryoprotectant molecules helps ligand solubilization while simul-
taneously providing an environment that ensures stabilization of
the protein and the interactions it makes within the crystal lattice.
Here we report on an extended set of multicomponent solutions
for crystal cryoprotection which includes additional components,
namely dioxane and butanediol and analyze the contribution of
dioxane toward ligand solubilization, alone and in conjunction
with other cryoprotectant components and its compatibility for
protein crystallization and crystal soaking. Dioxane has been
extensively used as an additive in macromolecular crystallization
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for its ability to mediate lattice interactions [4]. Concentrations of
3–10% are typical for its use as an additive, but at around 20–35% it
becomes an effective precipitant [5]. At similar concentrations,
DMSO can be problematic. High concentrations of DMSO affect
protein secondary structure and can lead to disordered proteins
[2].
Ligand insolubility is also a common problem in chemistry and
many compounds are insoluble in organic solvents. There is no
general rule on how to dissolve chemical molecules [6], and the
well-know phrase “similia similibus solvuntur” (polar solvents are
best to dissolve polar solutes and non-polar solvents for non-polar
solutes) is helpful only as a general guide. The strategy of using a
mixture of solvents to solubilize ligands is well known. Two or
more solvents together enhance the solubility of insoluble
compounds [7].
Here we report on an extended set of multicomponent solutions
for crystal cryoprotection (SM1-6) which includes two additional
components, dioxane and 2,3-butanediol. These solubilizing cryo-
preserving mixtures (mixes) have been designed for protein–
ligand co-crystallization experiments, soaking of hydrophobic
ligands into pre-formed crystals and for crystal cryoprotection
before ﬂash-cooling. The approach used to create cryoprotectant
solutions [3] with mixed compounds that inhibit ice formation, has
been extended by changing the composition, so as to increase their
ability to solubilize ligands. The mixes have been tested on human
transthyretin (TTR) [8] and on four matrix metalloproteinases
(MMP-8, 9, 12 and 13) with diffraction comparable to that obtained
with the use of CryoProtXTM (Molecular Dimensions, U.K. Ltd.)[3].
The term “mixes” will be used to refer to the mixture of
cryoprotectant compounds without buffer or precipitant; the
Fig. 1. Composition of the six ligand solubilizing mixed cryosolutions (cryomixes) SM1-6 shown graphically as cylinders.
When used to formulate a cryoprotectant solution for crystal soaking, the cryomixes represent 40% of the volume, 10% is assigned to the buffer and 50% to the precipitant-
water mixture that is 2 of the crystallization precipitant. For the solubilization of ligands, the cryomix is used directly to dissolve the ligand.
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Fig. 2. Resolution limitsz obtained from crystals of TTR, MMP-8, 9, 12 and 13 using various cryomixes containing varying lamounts of DMSO, dioxane and butanediol.
(For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Each data point corresponds to a data set, so that the width of the cryomix along the X-axis corresponds to the number of co-crystals tested. The resolution is shown in purple
and the vertical axis also shows the amounts of DMSO, dioxane and butanediol in the ﬁnal cryoprotectant (% v/v): in blue (dioxane), red (DMSO) and green (butanediol). The
composition of the cryomixes (except water) is given in the table below the ﬁgure (except SM1-6 mixes: Fig. 1).
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term “cryoprotectant solution” refers to the ﬁnal solution in which
crystals are soaked before vitriﬁcation at cryogenic temperatures.
2. Experimental
2.1. Composition of solubilizing cryoprotectant solutions
The composition of the solubilizing cryoprotectant solutions
has been chosen on the same basis as those developed for the
cryoprotection of crystals [3]. Compounds like ethanol and
methanol, that are excellent for ligand solubilization and to
reduce ice nucleation, have been excluded because their volatility
makes their use in vapor diffusion experiments and for the
cryoprotection of crystals impractical. This stems from the
difﬁculty to maintain a known solvent concentration during
manipulations because of evaporation. Additionally, evaporation
causes vortex-stirring so that it becomes difﬁcult to ﬁsh crystals
out of the swirling cryoprotectant solution into the cryoloop.
Compounds like ethylene glycol and propylene glycol are a better
choice since they have been used as cryoprotectant compounds
and in water co-solvent mixtures for pharmaceutical compounds
[7]. Dioxane, a non-volatile solvent that has been used as a
crystallization additive, not present in the previous design has
been added to the new “mixes” (Fig. 1). Another addition is 2,3-
butanediol, which is compatible with enzymatic activity [9].
The new solubilizing mixes have been formulated to maintain
consistency with the previous design [3]. Solutions for crystal
soaking are prepared in the same manner as the cryoprotectant
solutions. A 100 mL solution consists of 40 mL from one of the
ligand-solubilizing mixes, 10 mL (10) buffer and 50 mL (2)
precipitant (2: double the concentration used in the crystalliza-
tion to grow the crystals) (Fig.1). Experiments have been carried on
crystals of TTR, MMP12, MMP9, MMP8 and MMP13, cryoprotectant
solutions obtained with a variety of different precipitants to ensure
that crystals do not dissolve or crack when kept for 20 min or
overnight in the solutions, at the same temperature used for
crystallization.
2.2. Ligand solubilization options
For inhibitors poorly soluble or insoluble in DMSO, the mixed
solutions with DMSO/dioxane/ethylene glycol mixes of different
ratios were selected to improve ligand solubilization. DMSO,
ethylene glycol and dioxane belong to different selectivity classes:
III, IV and VI, respectively [10] and combination of these
compounds should cover a relatively wide range of selectivity
values to render water soluble a large variety of organic
compounds.
The target ligand concentration for soaking experiments was
set at 1–10 mM and three different options were considered and
tested. In the ﬁrst trial the ligand was solubilized at a concentration
of 10–30 mM in any of the six mixes SM1-6 (Fig.1). The ﬁnal ligand-
solubilization/cryo-solution for crystal soaking is composed of the
ligand-mix solution, 40% of the volume, the precipitant (at 2),
essential for crystal stability, represents 50% of the volume and the
remaining 10% is given by the buffer (at 10). The concentration of
the solvents is brought within the limits that avoid protein
denaturation and the ligand is within the target range of 1–10 mM.
The second option is to solubilize the ligand at 100–300 mM in
DMSO. The DMSO/ligand solution is then diluted 1:4 in SM3
(Fig. 1), the cryomix without DMSO. The resultant solution (40%), is
then mixed with the buffer (10%) and the precipitant (50%) so that
in the ﬁnal soaking solution the ligand is at 10–30 mM and the
DMSO at 10%. Solubilization of the ligand in dioxane is the third
option. The same procedure as for DMSO can be used for all SM1-6,
since a ﬁnal 20% dioxane is tolerated [11].
2.3. Preparation for soaking experiments
The SM1-6 solutions have been developed for a dual use, as
cryoprotectants and for ligand solubilization. The preparation of
the solutions for the soaking of ligands into crystals involves
several steps. While complete solubilization of the ligand is not
always necessary to achieve binding in the crystal. Success with
incompletely solubilized ligands has been achieved using long soak
periods [12,13]. This practise is not advised for short soaks. Initially
a series of mixtures are prepared with varying ratios of DMSO and
dioxane to evaluate the ability of these two solvents to solubilize
various ligands. Various DMSO/dioxane solvent mixtures are
prepared with the dioxane concentration increasing from 10% to
90%. After adding the ligand, each sample is analyzed under the
microscope to check for ligand crystals or insoluble residue so as to
identify which DMSO/dioxane ratio is best at solubilizing the
compound. After this initial step, one or two of the cryo-
solubilizing mixes which contained ethylene glycol, diethylene
glycol,1,2-propanediol, glycerol and 2,3-butanediol is selected. The
next step is to determine how long crystals are stable in the
solutions (prepared as suggested in Fig. 1). The third step is to
ensure that cryoprotectant solutions prepared with the selected
mixes perform in diffraction experiments in a manner comparable
to those in CryoProtXTM [3]. Compared to solubilization in just
dioxane or DMSO alone, the multicomponent mixes are more likely
to be compatible with protein structural integrity because the most
potentially denaturing components are present at lower concen-
trations. The presence of glycerol and similar compounds are
better known for their ability to stabilize rather than to denature
proteins provide additional protection against partial unfolding. In
a mix of dioxane and DMSO, in the absence of synergistic effects
whereby DMSO and dioxane would be better at denaturing
proteins than each component separately, the DMSO/dioxane mix,
where each of the two components help solubilize the ligand,
might be better tolerated by proteins. This assumption has been
subjected to experimental veriﬁcation in soaking and protein
crystallization tests. The solutions preserve TTR crystal integrity
for at least 20 min in ligand soaking experiments. In our tests, the
cryomixes SM1-6 were evaluated at different pH (acid-neutral-
basic) using several buffers for TTR [8] with different ligands. The
diffraction limit obtained with SM1-6 have been compared with
the mixes used in CryoProtXTM [3] (CM1-9) and with mixes CM10-
34 that also include dioxane and butanediol. The CM solutions
contain amounts of DMSO and dioxane that are well below the
concentrations that might cause protein denaturation. Although
MMP inhibitors do not require the SM mixes for ligand
solubilization, these solutions were used in order to evaluate
whether the extent of diffraction from MMP-inhibitor complex
crystals is reduced when the SM mixes are used. SM1-6 gave
results comparable to those obtained with the CM mixes (Fig. 2).
Equally outstanding diffraction was obtained for TTR crystals with
both the SM or CM mixes (Fig. 2). However, since susceptibility to
denaturation is likely to vary from one protein to another as some
proteins might be more prone to denaturation.
2.4. Co-crystallization experiments with TTR
The SM1-6 mixes were tested in co-crystallization experiments
with TTR [8] in the presence of curcumin and 16a-bromo-estradiol
solubilized DMSO/dioxane mixture. For co-crystallization, glycerol
and other diols are kept low. Even at low concentrations, glycerol
reduces the number of crystal nuclei formed and above 10% it
hinders crystal growth. In some experiments, SM3 was used as an
additive to the crystallization precipitant, in others, to increase the
strength of the precipitant, dioxane was used instead. Dioxane has
been used in co-crystallization experiments where, instead of PEG,
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ammonium sulfate is the main precipitant (example: 12% 1,4-
dioxane, 1.6 M ammonium sulfate in the crystallization of
P450 with camphor—afﬁnity 9.1 mM: PDB id 3LXI [12]). This
approach was tested with TTR, but high molecular weight
polyethylene glycol (PEG) was preferred and used more often.
The dioxane/PEG600 combination was also found effective for
certain inhibitors: (36–25% PEG 600, 15–40% dioxane, 0.2 M
imidazole malate, pH 5.5). In preparation for X-ray data collection,
the SM1-6 solutions were used in cryoprotectant solution
formulation (Fig. 1). A 6 mL drop of the cryosolution is placed on
a micro-bridge in an XRL plate with water in the reservoir to
maintain moisture. For low afﬁnity ligands, as is the case for most
TTR amyloidogenesis inhibitors and for the example given above, it
may be prudent to include ligand in the cryoprotectant. The ligand
solubilization procedure followed is as stated above. After ensuring
that the ligand does not precipitate or crystallize out, the protein–
ligand co-crystal is added, ﬂash-cooled in liquid nitrogen, or
soaked for 15–20 min beforehand at room temperature. The tests
were carried out on 152 ligands, most of which were co-
crystallized. Full data sets were collected for all these ligands to
create an extensive crystallographic database (see Supplementary
Data) from which the effect of DMSO, dioxane and 2,3-butanediol
on the resolution to which TTR and MMP co-crystals diffract can be
evaluated (Fig. 2). Of the TTR structures solved to date, all active
ligands have interpretable, even if weak electron density and some
ligands that offer less than 40% inhibition in turbidimetric assays
also appear bound to TTR. MMP inhibitors are more water soluble
and have better afﬁnities, so MMP co-crystals have been used only
to evaluate diffraction.
2.5. Use of dioxane in MMP-12 crystallization
Crystallization experiments were performed in CrysChem
sitting drop vapor diffusion plates with MMP-12 prepared as
previously described [14]. Drops consisting of 1 mL protein and
1 mL precipitant solutions were equilibrated by vapor diffusion and
stored in a cooled incubator at 20 C. Initial screening was carried
out with MMP-12 at 366 mM in a systematic manner following the
principles of reverse screening [15]. Single drop screening was
carried out with pre-prepared working solutions used for the
crystallization of other MMP-12 ligands to evaluate the change in
solubility of the glycoconjugated inhibitors [16] (Fig. 3). The
inhibitors (10 mM in 100% DMSO) were added with a 1.2-fold
stoichiometric excess. Four working solutions were tested: (A: 45%
PEG 4,000, 0.2 M imidazole piperidine, pH 8.5; B: 17% PEG 20,000,
200 mM imidazole malate, pH 8.5, 250 mM NaCl; C: 27% PEG
10,000, 150 mM imidazole piperidine, pH 8.5; D: 17% PEG 20,000,
250 mM NaCl, 100 mM Tris–HCl, pH 10.0). No protein precipitation
was observed in any of the trials. To stimulate the crystal formation
all drops were seeded with various polymorphs and 50 mL of a
booster solution consisting of 5 M NaCl was added to each reservoir
without success. Further trials with higher PEG concentrations and
different pH also failed to precipitate the MMP-12 complexed to
the glycoconjugated inhibitors. Seeding and a long series of NaCl
boosts (dehydration of the protein-precipitant drop by adding 5 M
NaCl to the reservoir) were ineffective.
To obtain crystals the following modiﬁcations were made:
1,4 dioxane (5–20%) was added to the precipitant and, if this was
not sufﬁcient, a higher protein concentration was used. Wild-type
protein was concentrated to 631 mM (with 10 mM acetohydroxa-
mic acid (AHA)—to prevent self-degradation of the proteinase) as
well as the less active MMP-12E219Q catalytic site mutants at
465 mM with 20 mM AHA. To further prevent proteolytic activity,
the inhibitors at 2 mM or 5 mM (in 100% DMSO) were added to the
protein solution in a volumetric ratio of 1:10. Crystals were
obtained by screening with working solution C and dioxane in the
range from 5 to 20%. Showers of small crystals appeared
spontaneously with MMP-12E219Q overnight in the drops contain-
ing 10–20% dioxane. Several changes were needed to improve
crystal size and to reduce the nucleation. Additions of ethylene
glycol or 30–50 mM NaCl in the precipitant effectively reduced
nucleation. Larger crystals were obtained within a week by
reducing the PEG and dioxane concentrations and reintroducing
seeding.
For data collection crystals were picked up with a cryoloop and
soaked for short period in selected mixtures of cryoprotectant
compounds before rapidly plunging in liquid nitrogen for
subsequent data collection at the Soleil synchrotron facility (Saint
Aubin, France) on beamline Proxima 2 and at the European
Synchrotron Radiation Facility (ESRF) in Grenoble (France) on
beamlines ID23-1 and ID23-2. The larger crystals diffracted to 1.6 Å
resolution, while data to 2.2 Å resolution was obtained for the
smaller ones (Fig. 2).
3. Results
3.1. Co-crystallization experiments
The SM1-6 mixes tested in co-crystallization experiments with
TTR in the presence of curcumin and 16a-bromo-estradiol
solubilized DMSO/dioxane mix were shown to be effective [8].
In these two cases, these hydrophobic compounds were solubilized
in a DMSO/dioxane mix and co-crystallized with a precipitant
consisting of high/low molecular weight PEG which helps to keep
the inhibitor soluble in the drop during crystal growth. This is
preferable to co-crystallization in high ionic strength which can
result in phase separation or in the ligand crystallizing out. Both of
these problems were encountered with TTR when crystallization
with these compounds was attempted with either ammonium
Fig. 3. Co-precipitants for protein crystallization. (a) Dioxane is used to supplement
the precipitating power of both ammonium sulfate and polyethylene glycol. (b) 2-
methyl-2,4-pentanediol (MPD) is commonly used as a precipitant, but similar
molecules are starting to used for similar applications. (c) In the crystallization of
glycoconjugated MMP-inhibitors, dioxane was added to the precipitant since the
precipitant power of polyethylene glycol was insufﬁcient to achieve supersatura-
tion of MMP-12.
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sulfate or sodium citrate. TTR crystallization requires high
concentration of these precipitants. We observed that the ligand
was segregated predominately the organic rich/salt poor phase
while the protein tended to concentrate in the salt rich phase. As
the vapor diffusion experiment progressed, the ligand concentrat-
ed and crystallized in it own phase while the protein crystallized in
the other phase. In high ionic strength crystallization experiments,
ligand insolubility is a problem that can be solved with long co-
crystallization periods or by adding solid ligand to the mother
liquor during the last crystallization phase: “Camphor saturates
the crystal solution after several days and the soaking time was
varied from 1 week to 1 month [12].” Alternatively, long soak times
can achieve similar results: “TTR–ligand complexes were prepared
from crystals soaked with a ﬁvefold molar excess of ligand for 3–
4 weeks to ensure saturation of both binding sites... [13]”. In our
experiments, the use of PEG in TTR co-crystallization experiments
has prevented ligand crystallization or precipitation in the drops,
avoided phase separation or the use of long incubation times in
soaking experiments.
However, when setting up the vapor diffusion experiments with
PEG under low salt conditions with ligand solubilized in a cryomix
we added an appropriate amount of cryomix to the reservoir to
avoid disequilibrium between the drop and the reservoir [17]. This
precaution is needed because the cryomixes contain glycerol and
other hygroscopic compounds that affect vapor diffusion equili-
bration [17]. Without this precaution the drop might increase in
volume rather than decrease. To remedy, 50 mL of booster solution
consisting of 5 M NaCl and acetic acid can be added to the reservoir
(500 mL), as soon as the problem is noted. Repeat additions may be
needed to restore equilibrium, to induce nucleation or to promote
crystal growth. Deliberately omitting to add the cryomix to the
reservoir can be used to combat excessive nucleation that can
occur during rapidly during protein and reservoir mixing. The
abundant nuclei dissolve during the phase the drop grows in size
and new crystals form later during the reversal when the booster
solution is added to the reservoir.
3.2. Solubilizing cryomix formulations
Even for those inhibitors that are highly soluble in DMSO, it may
still be preferable to use the mixed solutions for ligand
solubilization. Although in the mixed solutions the DMSO
concentration is only 25% and the extra components may not
contribute much to the solubilization, the advantage is gained in
the next dilution step. When preparing the ligand solution for
crystal soaking, 40% of solution with the dissolved ligand is mixed
with the buffer and precipitant. The DMSO concentration drops
down to 10%, but the additional components will contribute to
maintain the ligand in solution. When preparing the protein-ligand
complex for co-crystallization, the option of using the ligand
solubilized in DMSO, in DMSO/dioxane or in the SM1-6 depends on
the ligand and on the protein. The extra components will help
achieve a higher ﬁnal ligand concentration which could improve
homogeneity, but the diols will reduce crystal nucleation, which
may require seeding or other intervention to restore nucleation. In
a situation of excessive nucleation, as we encountered in the
crystallization of bi-functional ligands [18], a reduction in the
nucleation rate is welcome. In the TTR co-crystallization with
curcumin or 16a-bromo-estradiol all options were tested [8]. The
cryomix compositions were formulated to maximize ligand
solubility. The mixes were shown to be compatible with
cryoprotection of crystals. No ice rings were observed in the X-
ray data images. In cases where ice deposited on the crystals stored
in liquid nitrogen, because of excessive ambient moisture, the
annealing procedure [19] allowed ice to be cleared from the crystal
and diffraction observed was comparable to that of similar crystals.
3.3. Cryoprotectant and Ligand Soaking of Crystals
For all compounds tested so far, solubilization in the SM1-6
solutions, achieved concentrations of 1 mM in the soaking solution.
The solutions remained totally clear without the formation of
ligand crystals. The co-crystallization with curcumin was chal-
lenging as this ligand degraded during co-crystallization to yield
TTR-cocrystals with ferulic acid. With a replenishment step,
consisting of a 20 min soak in 1.5 mM curcumin, the ferulic acid
was exchanged for the intact ligand. To conﬁrm that such an
exchange is possible, the experiment was repeated with crystals
grown in the presence of 16a-bromo-estradiol that were soaked in
a cryoprotectant solution containing curcumin. Again the ligands
exchanged during the soaking step [8]. The ability of the SM1-6
solutions to act as cryo-preserving agents for the preparation of
crystals for X-ray data collection was tested on crystals of catalytic
domains of matrix metalloproteinases (MMP). MMP inhibitors are
relatively soluble and only exceptionally require special precau-
tions for their solubilization. The results of the cryoprotection tests
are shown diagrammatically in Fig. 2. Overall the SM1-6 solutions
performed in a comparable manner to other cryomix formulations
(CM mixes). The variations in diffraction quality between one
crystal and another was attributable mainly to crystal size and not
due to the cryoprotectant used. No crystal was lost in any of the
manipulations if the transfer from the crystallization mother liquor
was done with a large cryoloop. Some crystals were lost when the
transfer was carried out with loops 0.1 mm or smaller because the
surrounding liquid dried out. Thus crystals were placed in the cryo-
solution with a large loop and retrieved with a loop more
appropriate to the crystal size before ﬂash cooling. The compo-
nents of the cryomixes are hygroscopic and dry out at a much
slower rate compared to the mother liquor, facilitating all
subsequent manipulations. Some of the tests on MMP-12 were
carried out with concentrations of DMSO and dioxane higher than
recommended (Fig. 2) because dioxane was needed in the
crystallization, as explained below. The reduced diffraction might
not be due to the high levels of these components, but to the
difﬁculties in growing the crystals and their relative small size
compared to other crystals in the same graph.
3.4. Cryoprotectants as precipitants.
The SM1-6 mixes are formulated with balanced components
that neither precipitate nor solubilize protein but their use as
additives to the precipitant is unlikely to be neutral and their effect
needs to be understood in a case by case manner. In our laboratory,
small amounts of these mixes are effective in eliminating
denatured protein skins that can be found at times in vapor
diffusion experiments. The results obtained from the use of the
mixes need to be understood by varying the concentrations of each
component. Components like MPD, DMSO and propanediol can act
as precipitants as previously discussed [3]. Dioxane is well known
as a precipitant and as an additive [4] and butanediol like
propanediol, can also act as a precipitant [20]. The use of dioxane to
increment the precipitating power of polyethylene glycol has been
essential for obtaining crystals of the MMP-12 glycoconjugated
complexes.
4. Discussion
Increasing aqueous ligand solubility for co-crystallization and
ligand soaking is more complex that solving the same problem in
chemistry since the number of organic solvents that can be used is
smaller. The solvents need to be miscible in water and preferably
compatible with precipitants used in crystallization. Low ligand
afﬁnity for their target requires higher ligand concentrations
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compared to biological tests. The poor water solubility of initial
hits poses greater difﬁculties for co-crystallization since sufﬁcient
ligand concentrations are hard to achieve without high organic
solvent concentrations that can lead to denaturation of the target
protein. The use of mixed solvents achieves better ligand
solubilization because of an overall higher concentration of
organic solvents without leading to protein denaturation. For
co-crystallization and ligand soaking, the DMSO concentration can
in some cases be raised above the 10% level, but in others it disrupts
the integrity of the protein fold [2].
For ligand solubilization, dioxane complements DMSO, but does
not substitute for DMSO. Curcumin is completely soluble in DMSO
and not in dioxane, but the combination of the two solvents has
allowed the preparation of protein–ligand solutions suitable for
crystallization. The mixes when used as suggested in Fig. 1 achieve
high concentrations of DMSO and dioxane. Since denaturation will
vary from protein to protein, higher concentrations might be
tolerated by certain enzymes [11] but less by others. For difﬁcult
ligand solubilization cases, acetonitrile [11] or other suitable
volatile solvent can be tried. Unless their use is essential, volatile
solvents should be avoided since their use can complicate crystal
manipulation when the crystals are retrieved from the mother
liquor and transferred to the cryoprotectant and then to the liquid
nitrogen. The same problems arise when ethanol and propanol are
used as crystallization additives in vapor diffusion experiments.
Harvesting becomes difﬁcult as evaporation of the alcohols makes
the crystals swirl around. Getting crystals in perpetual movement
rapidly into the cryoloop is a challenge. Volatile compounds can
still be valuable for cryoprotection, but it may be more practical to
use alternative procedures, for example introducing alcohols into
crystals pre-mounted in cryoloops by vapor diffusion [21].
In ligand exchange experiments, like the one described for the
in situ steroid-curcumin exchange [8], the extra solubilizing effect
that come from all the components that belong to a different
selectivity classes comes into play. The ligands may require
different solubilization methods, and both ligands need to be
soluble simultaneously in the same soaking solution for the
exchange to take place rapidly. The ability of the mixes to solubilize
a wider set of ligands is realized when trying to exchange ligands in
preformed crystals rather than soaking a ligand into an empty
binding site. This strategy could be useful when crystals grow
easily with one ligand but not with another one. Curcumin was
soaked into the larger crystals of 16a-bromo-estradiol rather than
the other way round to ensure that even when large crystals are
used, exchange still takes place readily. To improve on the
exchange procedure, a two step procedure could be employed
to obtain a more complete exchange of the two ligands. After the
ﬁrst 20 min exchange-soak with the new ligand, the crystal should
be transferred to a new drop and the soak repeated, so as to wash
out the old ligand more thoroughly. Considering that the exchange
might be slower for high afﬁnity ligands, adding more exchange
steps, rather than longer exchange periods, should make the
exchange more efﬁcient in such cases.
Co-crystallization allows for protein conformational changes in
response to ligand binding. For this reason it should be preferred
over soaking. For co-crystallization it is important to separate the
solvents based on their ability to solubilize or precipitate the target
protein. Dioxane was used as a co-precipitant both in TTR [8] and
MMP-12 crystallization experiments to supplement the action of
polyethylene glycol. As needed, its effect can be counterbalanced
by glycerol and other diols that tend to increase protein solubility.
The use of the mixed solutions as part of the crystallization
precipitant, aids the solubilization of the ligands but also affects
protein supersaturation in the drop. The crystallization precipitant
for the TTR-ligand complexes was selected to work effectively for
the non-ligated protein with the belief that such crystallization
conditions would give crystals more predictably and translate into
more complexes with less material. Some failures with TTR were
noted when acidic ligands were co-crystallized under acidic
conditions. These compounds will be further studied using a
higher pH. Over all experiments on TTR and the four MMPs, the pH
range covered by the tests was 4.5–10, imposed by the
crystallization conditions of the proteins.
Dioxane was essential in the crystallization of glycoconjugated
MMP-inhibitor complexes (Fig. 3) to increase the precipitating
power of polyethylene glycol. The MMP-12 complex with these
ligands could not be crystallized with PEG alone. The glycosylated
ligand–protein complex was more difﬁcult to precipitate than
similar complexes without the sugar moiety. Without dioxane, to
achieve the same effect, the protein should have been concentrated
further. The strategy of adding dioxane is effective in extending the
use of a successful precipitant to crystallize more soluble ligand
complexes, without having to resort to higher protein concen-
trations. MPD, DMSO and propanediol might have been used
instead, as these compounds can also act as precipitants as
previously discussed [3]. Dioxane was chosen because it had been
beneﬁcial in previous work [4].
Butanediol like propanediol can act as a precipitant when used in
the 20–40% range [22]. Unfortunately, without more trials with
propanediol and butanediol to better understand the pros and cons
of their use as co-precipitants, the preference for proven additives
like dioxane and MPD will remain privileged. Propanediol is
becoming more popular as a precipitant (Bacillus subtilis manganese
transport regulator [23]; Listeria monocytogenes post-transcrip-
tional regulator Hfq [24]), but butanediol is seldom used. As robotic
screening expands, a greater variety of diols will be added to
crystallization screens. MPD in the form 2-methyl-2,4-pentanediol
has been extensively used for the crystallization of proteins [25]
while other isomers of the compound had been ignored. Recently, 3-
methyl-1,5-pentanediol (Fig. 3) has been used to obtain large
crystals of glycoside hydrolase [26]. Cryoprotection cum ligand-
solubilization mixes are likely to follow the trend and incorporate a
wider spectrum of molecules to achieve higher ligand concen-
trations of poorly water soluble ligands of pharmaceutical interest.
The addition of 2,3-butanediol in the mixes contributes to
ligand solubilization and to cryoprotection. This compound was
considered as an antifreeze agent more than 60 years ago [27]. It is
used in cryobiology because of important advantages in super-
cooling and vitriﬁcation at lower concentrations [22] compared to
other cryoprotecting agents. For ﬂash-cooling of protein crystals
this compound has performed well in the solubilizing mixtures
reported here and in other experiments as a complement to the
CryoProtX solutions [3].
To conclude, the use of biologically compatible mixed solvents
is likely to expand the range of projects that can be tackled by X-ray
crystallography, or, in some cases, only simplify procedures that
used to span weeks or months, with uncertain results. A similar
approach, using mixed solvents instead of DMSO alone, could be
beneﬁcial to a wider range of biological applications.
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